Vascular dementia: A review of recent evidence for prevention and treatment

Current Neurology and Neuroscience Reports

Volumn 9, Issue 6, 2009, Pages 437-442

  Kirshner, Howard S ^a  

^a VANDERBILT UNIVERSITY MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

DONEPEZIL; GALANTAMINE; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; MEMANTINE; PROTEIN GAX; PROTEIN MEOX2; REGULATOR PROTEIN; UNCLASSIFIED DRUG;

ALZHEIMER DISEASE; BINSWANGER ENCEPHALOPATHY; BLOOD PRESSURE REGULATION; BRAIN INFARCTION; CADASIL; CEREBROVASCULAR ACCIDENT; DRUG EFFICACY; GENE EXPRESSION; HUMAN; LIFESTYLE MODIFICATION; METABOLIC SYNDROME X; MULTIINFARCT DEMENTIA; NEUROPATHOLOGY; REVIEW; RISK FACTOR; RISK REDUCTION; SYSTOLIC HYPERTENSION; VASCULAR DISEASE; WHITE MATTER;

ANIMALS; COGNITION DISORDERS; DEMENTIA, VASCULAR; HUMANS; RISK FACTORS;

EID: 70350175981     PISSN: 15284042     EISSN: None     Source Type: Journal    
DOI: 10.1007/s11910-009-0065-y     Document Type: Review

References (62)

1. Roman GC: On the history of lacunes, etat crible, and the white matter lesions of vascular dementia. Cerebrovasc Dis 2002, 13(Suppl 2): 1-6.
2. Zhang-Nunes SX, Maat-Schieman ML, van Duinen SG, et al.: The cerebral beta-amyloid angiopathies: Hereditary and sporadic. Brain Pathol 2006, 16: 30-39.
3. Hachinski VC, Iliff LD, Zilkha E, et al.: Cerebral blood flow in dementia. Arch Neurol 1975, 32:632-637.
4. Rosen WG, Terry RD, Fuld PA, et al.: Pathological verification of ischemic score in differentiation of dementias. Ann Neurol 1980, 7:486-448.
5. Hachinski V: Aascular dementia: a radical redefinition. Dementia 1994, 5:130-132.
6. Chui HC, Victoroff JI, Margolin D, et al.: Criteria for the diagnosis of ischemic vascular dementia proposed by the State of California Alzheimer's Disease Diagnostic and Treatment Centers. Neurology 1992, 42:473-480.
7. Roman GC, Tatemichi TK, Erkinjuntti T, et al.: Vascular dementia: diagnostic criteria for research studies. Report of the NINDS-AIREN International Work Group. Neurology 1993, 43:250-260.
8. Knopman D, Boland LL, Mosley T, et al.: For the Atherosclerosis Risk in Communities (ARIC) Study Investigators: Cardiovascular risk factors and cognitive decline in middleaged adults. Neurology 2001, 56:42-48.
9. Forette F, Seux ML, Staessen JA, et al.: Prevention of dementia in randomised double-blind placebo-controlled Systolic Hypertension in Europe (Syst-Eur) trial. Lancet 1998, 352:1347-1351.
10. Hanon O, Forette FL Prevention of dementia: lessons from SYST-EUR and PROGRESS. J Neurol Sci 2004, 226:71-74.
11. Yaffe K, Kanaya A, Lindquist K, et al.: The metabolic syndrome, inflammation, and rise of cognitive decline. JAMA 2004, 292:2237-2242.
12. Solomon A, Kareholt I, Ngandu T: Serum cholesterol changes after mid-life and late-life cognition: Twenty-one year follow-up. Neurology 2007, 68:751-756.
13. Shumaker SA, Legault C, Rapp SR, et al.: Estrogen plus progestin and the incidence of dementia and mild cognitive impairment in postmenopausal women. The Women's Health Initiative Memory Study: A randomized controlled trial. JAMA 2003, 289:2651-2652.
14. Rapp SR, Espeland MA, Shumaker SA: Effect of estrogen plus progestin on global cognitive function in post menopausal women. The Women's Health Initiative Memory Study: A randomized controlled trial. JAMA 2003, 289:2663-2672.
15. Bos MJ, Van Rijn MJ, Witteman JC, et al.: Incidence and prognosis of transient neurological attacks. JAMA 2007, 298:2877-2785.
16. Tatemichi TK, Paik M, Bagiella E, et al.: Risk of dementia after stroke in a hospitalized cohort: Results of a longitudinal study. Neurology 1994, 44:1885-1891.
17. Kokmen E, Whisnant JP, O'Fallon WM, et al.: Dementia after ischemic stroke: A population-based study in Rochester, Minnesota (1960-1984). Neurology 1996, 46:154-159.
18. Pohjasvaara T, Mantyla R, Salonen O, et al.: How complex interactions of ischemic brain infarcts, white matter lesions, and atrophy relate to poststroke dementia. Arch Neurol 2000, 57:1295-1300.
19. Stebbins GT, Nyenhuis DL, Wang C, et al.: Gray matter atrophy in patients with ischemic stroke with cognitive impairment. Stroke 2008, 39:785-793.
20. Szirmai I, Vastagh I, Szombathelyi E, Kamondi A: Strategic infarcts of the thalamus in vascular dementia. J Neurol Sci 2002, 203-204:91-97.
21. Williamson JB, Nyenhuis DL, Pedelty L, et al.: Baseline differences between vascular cognitive impairment no dementia reverters and non-reverters. J Neurol Neurosurg Psychiatry 2008, 79:1208-1214.
22. Leary MC, Saver JL: Annual incidence of first silent stroke in the United States: A preliminary estimate. Cerebrovasc Dis 2003, 16:280-285.
23. Vermeer SE, Prins ND, den Heijer T, et al.: Silent brain infarcts and the risk of dementia and cognitive decline. N Engl J Med 2003, 348:1215-1222.
24. Hachinski VC, Potter P, Merskey H: Leuko-araiosis. Arch Neurol 1987, 44:21-23.
25. Steingart A, Hachinski VC, Lau C, et al.: Cognitive and neurologic findings in subjects with diffuse white matter lucencies on computed tomographic scan (leuko-araiosis). Arch Neurol 1987, 44:32-35.
26. Kertesz A, Polk M, Carr T: Cognition and white matter changes on magnetic resonance imaging in dementia. Arch Neurol 1990, 47:387-391.
27. Breteler MMB, van Swieten JC, Bots ML, et al.: Cerebral white matter lesions, vascular risk factors, and cognitive function in a population-based study: The Rotterdam Study. Neurology 1994, 44:1246-1252.
28. Moser DJ, Cohen RA, Paul RH, et al.: Executive function and magnetic resonance imaging subcortical hyperintensities in vascular dementia. Neuropsychiatry Neuropsychol Behav Neurol 2001, 14:89-92.
29. McPherson SE, Cummings JL: Neuropsychological aspects of vascular dementia. Brain Cogn 1996, 31:269-282.
30. Reed BR, Mungas DM, Kramer JH, et al.: Profiles of neuropsychological impairment in autopsy-defined Alzheimer's disease and cerebrovascular disease. Brain 2007, 130:731-739.
31. Knopman DS, Parisi DS, Boeve BF, et al.: Vascular dementia in a population-based autopsy study. Arch Neurol 2003, 60:569-575.
32. Schneider JA, Boyle PA, Arvanitakis Z, et al.: Subcortical infarcts, Alzheimer's disease pathology, and memory function in older persons. Ann Neurol 2007, 62:59-66.
33. Kovari E, Gold G, Herrmann FR, et al.: Cortical microinfarcts and demyelination affect cognition in cases at high risk for dementia. Neurology 2007, 68:927-931.
34. Chui H, Zarow C, Mack WJ, et al.: Cognitive impact of subcortical vascular and Alzheimer's disease pathology. Ann Neurol 2006, 60:677-687.
35. Seo SW, Lee BH, Kim E-J, et al.: Clinical significance of microbleeds in subcortical vascular dementia. Stroke 2007, 38:1949-1951.
36. Viswanathan A, Chabriat H: Cerebral microhemorrhages. Stroke 2006, 37:550-555.
37. Vagnucci AH Jr, Li WW: Alzheimer's disease and angiogenesis. Lancet 2003, 361:605-608.
38. Wu Z, Guo H, Chow N, et al.: Role of the MEOX2 homeobox gene in neurovascular dysfunction in Alzheimer's disease. Nat Med 2005, 11:899-904.
39. Dichgans M, Mayer M, Uttner I, et al.: The phenotypic spectrum of CADASIL: Clinical findings in 102 cases. Neurology 1998, 44:731-739.
40. Jouvent E, Viswanathan A, Mangin JF, et al.: Brain atrophy is related to lacunar lesions and tissue microstructural changes in CADASIL. Stroke 2007, 38:1786-1790.
41. Caplan LR, Schoene WC: Clinical features of subcortical arteriosclerotic encephalopathy (Binswanger disease). Neurology 1978, 28:1206-1215.
42. Babikian V, RoppAr AH: Binswanger's disease: a review. Stroke 1987, 18:1-12.
43. Beal MF, Williams RS, Richardson EP, Fisher CM: Cholesterol embolism as a cause of transient ischemic attacks and cerebral infarction. Neurology 1981, 31:860-865.
44. Sneddon IB: Cerebro-vascular lesions and livedo reticularis. Br J Dermatol 1965, 77:180-185.
45. Wright RA, Kokmen E: Gradually progressive dementia without discrete cerebrovascular events in a patient with Sneddon's syndrome. Mayo Clin Proc 1999, 74:57-61.
46. Moore PM, Richardson B: Neurology of the vasculitides and connective tissue diseases. J Neurol Neurosurg Psychiatry 1998, 65:10-22.
47. Fieschi C, Rasura M, Anzini A, Beccia M: Central nervous system vasculitis. J Neurol Sci 1998, 8:159-171.
48. Kirk A, Kertesz A, Polk MJ: Dementia with leukoencephalopathy in systemic lupus erythematosus. Can J Neurol Sci 1991, 18:344-348.
49. Susac J: Susac's syndrome. The triad of microangiopathy of the brain and retina with hearing loss in young women. Neurology 1994, 44:591-593.
50. Moore PM: Diagnosis and management of isolated angiitis of the central nervous system. Neurology 1989, 39:167-173.
51. Perret G, Nishioka H: Report on the cooperative study of intracranial aneurysms and subarachnoid hemorrhage. Section VI. Arteriovenous malformations. J Neurosurg 1966, 25:467-490.
52. DeGirolami V, Haas ML, Richardson EP Jr: Subacute diencephalic angioencephalopathy: A clinicopathological case study. J Neurol Sci 1974, 22:197-210.
53. Gorelick PB, Erkinjuntti T, Hofman A, et al.: Prevention of vascular dementia. Alzheimer Dis Assoc Disord 1999, 13(Suppl 3):S131-S139.
54. Jick H, Zornberg GL, Jick SS, et al.: Statins and the risk of dementia. Lancet 2000, 356:1627-1631.
55. Erkinjuntti T, Kurz A, Gauthier S, et al.: Efficacy of galantamine in probable vascular dementia and Alzheimer's disease combined with cerebrovascular disease: A randomised trial. Lancet 2002, 359:1283-1290.
56. Black S, Roman GC, Geldmacher DS, et al.: Efficacy and tolerability of donepezil in vascular dementia: Positive results of a 24-week, multicenter, international, randomized, placebo-controlled clinical trial. Stroke 2003, 34:2323-2330.
57. Wilkinson D, Doody R, HelmA R, et al.: Donepezil in vascular dementia: a randomized, placebo-controlled study. Neurology 2003, 61:479-486.
58. Aguilar M, Roman G, Black S, et al.: Efficacy and safety of donepezil in vascular dementia: Results from the largest double-blind trial in vascular dementia [abstract P4-439]. Presented at the 10th International Conference on Alzheimer's Disease and Related Disorders. Madrid, Spain; July 15-20, 2006.
59. Kavirajan H, Schneider LS: Efficacy and adverse effects of cholinesterase inhibitors and memantine in vascular dementia: A meta-analysis of randomized clinical trials. Lancet Neurol 2007, 6:782-792.
60. Dichgans M, Markus HS, Salloway S, et al.: Donepezil in patients with subcortical vascular cognitive impairment: A randomized double-blind trial in CADASIL. Lancet Neurol 2008, 7:310-318.
61. Wilcock G, Mobius HJ, Stoffler A; MMM 500 Group: A double-blind, placebo-controlled multicentre study of memantine in mild to moderate vascular dementia (MMM 500). Int Clin Psychopharmacol 2002, 17:297-305.
62. Orgogozo JM, Rigaud AS, Stoffler A, et al.: Efficacy and safety of memantine in patients with mild to moderate vascular dementia: A randomized, placebo-controlled trial (MMM 300). Stroke 2002, 33:1834-1839.